This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Will Moderna Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Moderna
Top Stock Trades to Beat Coronavirus Blues in April
by Tirthankar Chakraborty
The coronavirus pandemic has hit markets bad. But investors shouldn't shun stocks in April but should instead look for avenues to invest in areas under focus owing to rise in infected cases.
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $30.48, moving +1.43% from the previous trading session.
Translate Bio, Sanofi to Jointly Develop Coronavirus Vaccine
by Zacks Equity Research
Translate Bio (TBIO) gains on collaboration with Sanofi for a mRNA vaccine development for COVID-19.
Top Ranked Momentum Stocks to Buy for March 30th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 30th
Why Is Moderna (MRNA) Up 6.8% Since Last Earnings Report?
by Zacks Equity Research
Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences
3 Best U.S. Stocks Immune to Coronavirus Jitters
by Manaswita Ghosh Dutta
The pandemic may be taking a toll on markets right now but this temporary phase offers investors a window to buy equities that have a record of performing better than the broader markets.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
How To Play The W-Shaped Recovery
by Daniel Laboe
Patience is the name of the game during market downturns
Novavax Rallies as Influenza Vaccine Meets All Goals in Study
by Zacks Equity Research
Novavax's (NVAX) NanoFlu, the influenza vaccine candidate for adults aged 65 years and older, meets all the primary and secondary endpoints in late-stage study. Shares rise.
Top 5 Drug Stocks To Stop The Coronavirus Pandemic
by Daniel Laboe
It is only a matter of time before this virus anxiety is a thing of the past.
Coronavirus Drug Development Race to Boost These 4 Stocks
by Zacks Equity Research
Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.
Aytu BioScience to Issue Coronavirus Rapid Test in North America
by Zacks Equity Research
Aytu BioScience (AYTU) expands the right to distribute and commercialize the COVID-19 IgG/IgM rapid test across the United States, Canada and Mexico. Stock jumps.
Hoth Surges on Collaboration With Voltron for COVID-19 Vaccine
by Zacks Equity Research
Hoth (HOTH) soars following a joint venture with Voltron Therapeutics for a vaccine for COVID-19.
Axsome Expedites Completion Timeline of AD Study on AXS-05
by Zacks Equity Research
Axsome (AXSM) speeds up the evaluation time of AXS-05 under the phase II/III ADVANCE-1 study for Alzheimer's disease agitation to ensure safety of patients amid the COVID-19 pandemic.
Moderna (MRNA) Stock Moves -0.46%: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $28.14, marking a -0.46% move from the previous day.
Gilead's HCV Drug Epclusa Gets FDA Nod for Expanded Age Group
by Zacks Equity Research
The FDA approves Gilead's (GILD) sNDA for Epclusa to treat chronic hepatitis C infection in children aged six years and above or weighing at least 17 kg.
Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.
The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals
Roche to Evaluate Actemra for Severe COVID-19 Pneumonia
by Zacks Equity Research
Roche (RHHBY) works with the FDA to evaluate the safety and efficacy of rheumatoid arthritis drug, Actemra, in severe COVID-19.
4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis
by Debanjana Dey
Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.
Drugs or Vaccines: Which Will Be More Crucial Against Coronavirus?
by Ekta Bagri
Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.
Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
The Zacks Analyst Blog Highlights: CLX, MRNA, TDOC and ATVI
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CLX, MRNA, TDOC and ATVI